| USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS |
USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS |
95%
|
USAspending awards from Department of Veterans Affairs: $600,808 across 10 awards. 36C25025P0025 PHARMACEUTICAL DRUG; 36C26226N0373 EMERGENCY THIOLA 100 MG TABLETS; 36C26124N0539 SPARSENTAN 400MG TAB… |
| FILSPARI |
FILSPARI |
92%
|
The Company sells FILSPARI to two direct-to-patient specialty pharmacies in the United States |
| PATIENTS |
PATIENTS |
92%
|
The Company sells its tiopronin products to patients and pharmacies, with distribution facilitated through a single direct-to-patient distributor |
| SPECIALTY-PHARMACIES |
SPECIALTY-PHARMACIES |
92%
|
The Company sells its products to specialty pharmacies and through direct-to-patient distributors worldwide |
| THIRD-PARTY-PAYERS |
THIRD-PARTY-PAYERS |
92%
|
The Company receives payments from sales of its tiopronin products, primarily through third party payers |
| BMY |
Bristol-Myers Squibb Company |
72%
|
sh share-based compensation, license fees, milestones under license agreements, costs paid to third-party contractors to perform research, conduct clinical trials, and develop drug materials and deli… |
| BMY |
Bristol-Myers Squibb Company |
72%
|
Reciprocal relationship from BMY graph: Reciprocal relationship from TVTX graph: Reciprocal relationship from BMY graph: Reciprocal relationship from TVTX graph: Reciprocal relationship from BMY grap… |
| BMYMP |
Bristol-Myers Squibb Co |
72%
|
Reciprocal relationship from BMYMP graph: Reciprocal relationship from TVTX graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from TVTX graph: sh share-based compensation, lice… |
| BMYMP |
Bristol-Myers Squibb Co |
72%
|
sh share-based compensation, license fees, milestones under license agreements, costs paid to third-party contractors to perform research, conduct clinical trials, and develop drug materials and deli… |
| CSLLY |
CSL Limited |
72%
|
Reciprocal relationship from CSLLY graph: Reciprocal relationship from TVTX graph: s of effective sales personnel; • lack of complementary products to be offered by sales personnel, which may put us … |
| CSLLY |
CSL Limited |
72%
|
s of effective sales personnel; • lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies that have more extensive produc… |
| JPM-PD |
JPMorgan Chase & Co. |
72%
|
ny of our product candidates could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Some of our contracts do not contain limi… |
| JPM-PD |
JPMorgan Chase & Co. |
72%
|
Reciprocal relationship from JPM-PD graph: Reciprocal relationship from TVTX graph: Reciprocal relationship from JPM-PD graph: Reciprocal relationship from TVTX graph: Reciprocal relationship from JP… |
| MIRM |
Mirum Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from MIRM graph: 808) (“Topic 808”) and determines whether such arrangements involve joint operating activities performed by parties that are both active participants in the a… |
| MIRM |
Mirum Pharmaceuticals, Inc. |
72%
|
oducts in development to continue our operations until we can achieve sustained profitability and positive cash flows from operating activities. Additional funds may not be available to us when we ne… |
| ORANY |
ORANY |
72%
|
Reciprocal relationship from ORANY graph: Reciprocal relationship from TVTX graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from TVTX graph: Reciprocal relationship from ORAN… |
| ORANY |
ORANY |
72%
|
s of effective sales personnel; • lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies that have more extensive produc… |
| VERA |
Vera Therapeutics, Inc. |
72%
|
Reciprocal relationship from VERA graph: experienced any significant delays in obtaining any raw materials from our suppliers, we cannot provide assurance that we will not face shortages from one or … |
| ALL-WALES-MEDICINES-STRATEGY-GROUP |
ALL-WALES-MEDICINES-STRATEGY-GROUP |
62%
|
ologies, including new medicinal products, and providing the basis for cooperation at EU level for joint clinical assessments in these areas. The Regulation permits EU Member States to use common HTA… |
| CHUGAI-PHARMACEUTICAL-CO-LTD |
CHUGAI-PHARMACEUTICAL-CO-LTD |
62%
|
ack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies that have more extensive product lines; and • unforeseen delays, c… |
| COORDINATION-GROUP |
COORDINATION-GROUP |
62%
|
to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to have a false claim paid. This includes claims made to programs w… |
| LIGAND-PHARMACEUTICALS-INC |
LIGAND-PHARMACEUTICALS-INC |
62%
|
sh share-based compensation, license fees, milestones under license agreements, costs paid to third-party contractors to perform research, conduct clinical trials, and develop drug materials and deli… |
| ORPHAN-TECHNOLOGIES-LIMITED |
ORPHAN-TECHNOLOGIES-LIMITED |
62%
|
sh share-based compensation, license fees, milestones under license agreements, costs paid to third-party contractors to perform research, conduct clinical trials, and develop drug materials and deli… |
| PHARMAKRYSTO-LIMITED |
PHARMAKRYSTO-LIMITED |
62%
|
equity securities of Renalys at any time prior to the top-line results of the Phase 3 trial in Japan (“Buyout Right”). Under the Renalys License Agreement, Renalys will be responsible for all develop… |
| RENALYS-PHARMA-INC |
RENALYS-PHARMA-INC |
62%
|
the Scope of ASC 808, Collaborative Arrangements of active participation by both parties and exposures to significant risks and rewards dependent on the commercial success of the activities. Both par… |
| SI |
Shoulder Innovations, Inc. |
62%
|
Reciprocal relationship from SI graph: Reciprocal relationship from TVTX graph: ny of our product candidates could result in delays in our regulatory approval efforts and significantly increase our c… |
| SILVERGATE-CAPITAL-CORP |
SILVERGATE-CAPITAL-CORP |
62%
|
ny of our product candidates could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Some of our contracts do not contain limi… |
| TORRENT-PHARMACEUTICALS-LIMITED |
TORRENT-PHARMACEUTICALS-LIMITED |
62%
|
ing the basis for cooperation at EU level for joint clinical assessments in these areas. The Regulation foresees a three-year transitional period and will permit EU Member States to use common HTA to… |
| VIFOR-PHARMA-GROUP |
VIFOR-PHARMA-GROUP |
62%
|
anage adequate numbers of effective sales personnel; • lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies that have … |
